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Ischemic stroke is a major cause of death and 
permanent disability in industrialized countries 
(1). Studies on the use of anticoagulant drugs in 
acute cerebral ischemia have shown no overall 
benefi  t, with decreases in lesion progression or 
stroke recurrence being off  set by an increase in 
hemorrhage (2). Furthermore, long-term anti-
coagulation for prophylaxis to prevent throm-
boembolic events is inevitably associated with 
an increase in bleeding-related morbidity and 
mortality (3). Thus, it is highly desirable to 
identify novel targets for safe anticoagulation to 
treat stroke and other thrombotic disorders.
In the classic cascade or waterfall models of 
blood coagulation (4, 5), initiation of the com-
plex process that culminates in fi  brin forma-
tion in vitro can occur through either of two 
converging cascades, designated the extrinsic 
and intrinsic pathways. The factor VIIa–tissue 
factor (TF) complex comprises the extrinsic 
pathway (for reviews see reference  <CIT>6 </CIT>), and 
defi  ciency of either factor VIIa or TF severely 
impairs blood coagulation in vivo (7, 8). On 
the other hand, hereditary defi  ciency of factor 
XII (FXII; Hageman factor), the protease that 
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Formation of fi  brin is critical for limiting blood loss at a site of blood vessel injury (hemo-
stasis), but may also contribute to vascular thrombosis. Hereditary defi  ciency of factor XII 
(FXII), the protease that triggers the intrinsic pathway of coagulation in vitro, is not asso-
ciated with spontaneous or excessive injury-related bleeding, indicating FXII is not required 
for hemostasis. We demonstrate that defi  ciency or inhibition of FXII protects mice from 
ischemic brain injury. After transient middle cerebral artery occlusion, the volume of in-
farcted brain in FXII-defi  cient and FXII inhibitor–treated mice was substantially less than in 
wild-type controls, without an increase in infarct-associated hemorrhage. Targeting FXII 
reduced fi  brin formation in ischemic vessels, and reconstitution of FXII-defi  cient mice with 
human FXII restored fi  brin deposition. Mice defi  cient in the FXII substrate factor XI were 
similarly protected from vessel-occluding fi  brin formation, suggesting that FXII contributes 
to pathologic clotting through the intrinsic pathway. These data demonstrate that some 
processes involved in pathologic thrombus formation are distinct from those required for 
normal hemostasis. As FXII appears to be instrumental in pathologic fi  brin formation but 
dispensable for hemostasis, FXII inhibition may offer a selective and safe strategy for 
preventing stroke and other thromboembolic diseases.
CORRESPONDENCE
Thomas Renné:
thomas@renne.net
C. Kleinschnitz, G. Stoll, and M. Bendszus contributed 
equally to this work.
H.-U. Pauer’s present address is Center for Hemostasis and 
Thrombosis Research, Vascular Biology Center, Beth Israel 
Deaconess Medical Center and Harvard Medical School, 
Boston, 02215 MA.
The online version of this article contains supplemental material.514  FXII AND STROKE | Kleinschnitz et al.
triggers the intrinsic pathway, is not associated with sponta-
neous hemorrhage or excessive injury-related bleeding in 
vivo (9, 10). These observations have led to revisions of the 
classic coagulation models that do not require FXII for fi  brin 
formation (11).
We now demonstrate that defi   ciency or inhibition of 
FXII protects mice from ischemic brain injury in an experi-
mental stroke model, without an increase in bleeding com-
plications. Together with our previous fi  ndings that arterial 
thrombus formation triggered by artifi  cial vessel injuries is 
defective in FXII-null mice (12), the data indicate that FXII 
inhibition may off  er a selective and safe strategy for treatment 
or prophylaxis of vessel-occluding diseases. Furthermore, 
these novel fi  ndings suggest that the paradigm that pathologic 
thrombus formation is caused by dysregulation of the pro-
cesses that normally prevent blood loss at a wound site may 
be incomplete and requires revision.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
To investigate the functions of FXII in hemostasis and throm-
bosis during ischemic stroke, we used FXII-defi  cient mice. 
Like their FXII-defi   cient human counterparts, FXII-null 
mice (FXII−/−) develop normally and exhibit no spontane-
ous or injury-related hemorrhage, despite having very pro-
longed activated partial thromboplastin times (aPTT) clotting 
times (12) (a test of intrinsic pathway-initiated coagulation). 
Other studies of hemostasis, as well as cardiovascular char-
acterization, did not reveal diff  erences between WT and 
FXII−/− mice (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20052458/DC1). As previous analyses 
of FXII−/− mice using chemical and mechanical vessel in-
juries in various arterial beds indicated defective thrombus 
stability (12), we assessed the contribution of FXII to the de-
velopment of neuronal damage after transient cerebral isch-
emia in a model that depends on thrombus formation in 
microvessels downstream from a middle cerebral artery 
(MCA) occlusion (13, 14).
To initiate transient cerebral ischemia, a thread was ad-
vanced through the carotid artery into the MCA and allowed 
to remain for 1 h (transient MCA occlusion; tMCAO), re-
ducing regional cerebral fl  ow by >90% (8 ± 2% and 9 ± 2% 
of baseline in FXII−/− and WT mice, respectively). 15 min 
after removal of the thread, laser-doppler ultrasound revealed 
comparable recovery of MCA blood fl  ow (FXII−/− 59 ± 8% 
and WT 59 ± 5%). 24 h after reperfusion, the infarct vol-
umes in FXII−/− animals assessed by triphenyltetrazolium 
chloride (TTC) staining were dramatically reduced to <50% 
of the infarct volumes in WT mice (Fig. 1, A and B). [ID]FIG1[/ID] The re-
duction in infarct size is functionally relevant, as the Beder-
son score assessing global neurological function (Fig. 1 C; 
P < 0.01) and the grip test that specifi  cally measures motor 
function and coordination (FXII−/− 3.5 ± 0.5 and WT 1.9 ± 
1.3; P < 0.01) were signifi  cantly better in FXII−/− mice 
than in WT mice.
To prove that the protective eff  ect was specifi  cally related 
to FXII defi  ciency and not to a secondary eff  ect of the defi  -
ciency state, we reconstituted FXII−/− mice with human 
FXII in an attempt to “rescue” the WT phenotype. Intrave-
nous infusion of human FXII (2 μg/g body weight) normal-
ized the aPTT (29 ± 5 s for FXII−/−  + human FXII 
compared with 27 ± 4 s for WT and 72 ± 20 s for FXII−/−) 
and restored susceptibility to ischemic brain damage after 
  tMCAO. Infarct volumes (56 ± 17 mm3; Fig. 1 B) and neu-
rological outcome parameters for FXII−/− mice treated with 
human FXII (Bederson score 3.2 ± 0.4; Fig. 1 C) were in-
distinguishable from WT mice. Importantly, FXII defi  ciency 
and FXII substitution did not aff  ect normal injury-related 
  coagulation as assessed by bleeding times in a tail amputation 
assay (FXII−/− 314 ± 78 s, FXII−/− + human FXII 301 ± 
56 s, and WT 288 ± 81 s; n = 12 for each group).
Collectively, the rescue experiments provide strong evi-
dence that the protection conferred by FXII defi  ciency in 
the tMCAO model is caused by the absence of plasma FXII. 
Furthermore, FXII may function similarly in mice and hu-
mans. Indeed, in a recent study of 21 patients with severe 
(homozygous) FXII defi  ciency no patient developed an arte-
rial thrombotic event during a 15-yr follow-up period (15). 
However, larger epidemiologic studies are clearly needed to 
conclusively show a thromboprotective eff  ect for FXII defi  -
ciency in humans.
Figure 1.  Infarct volumes and functional outcomes 24 h after 
focal cerebral ischemia in WT and FXII−/− mice, and in FXII−/− mice 
infused with human FXII. (A) Representative images of three corre-
sponding coronal sections of WT (left), FXII−/− (middle), and FXII−/− mice 
reconstituted with human FXII (huFXII, 2 μg/g body weight i.v. 10 min 
before the MCAO; right) stained with TCC. (B) Brain infarct volumes in WT 
(n = 18), FXII−/− (n = 18), and FXII−/− mice reconstituted with huFXII 
(n = 8); **P < 0.01. (C) Neurological Bederson score assessed at day 1 
after tMACO for WT (n = 18), FXII−/− (n = 18), and huFXII-treated FXII−/− 
animals (n = 8); **P < 0.01. n.s., not signifi  cant.JEM VOL. 203, March 20, 2006  515
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In addition to its role in the intrinsic coagulation path-
way, FXII may initiate or be involved in other proteolytic 
cascades, including the complement and kallikrein-kinin sys-
tems. The protease factor XI (FXI) is the primary substrate 
for activated FXII in the intrinsic pathway. Although FXII-
defi  cient humans do not have a hemorrhagic condition, hu-
mans lacking FXI suff  er from a mild to moderate bleeding 
disorder (16). If the prothrombotic eff  ect of FXII in the 
  tMCAO model is mediated through FXI activation, then 
FXI−/− mice should be protected from ischemic stroke simi-
larly to FXII−/− animals. Indeed, in the tMCAO model brain 
infarct volumes were markedly diminished in FXI−/− mice 
compared with WT controls (27 ± 24 mm3 and 46 ± 21 
mm3, respectively, P < 0.05; Fig. 2 A). [ID]FIG2[/ID] These fi  ndings sup-
port the concept that activated FXII activates FXI during 
thrombus formation in WT mice, and are consistent with 
studies in primates and rabbits demonstrating that inhibiting 
FXI has antithrombotic eff  ects (17, 18). In contrast to defi  -
ciencies of FXII or FXI, defi  ciency of factor IX, a substrate 
for both activated FXI in the intrinsic pathway and factor 
VII/TF (19), results in a severe bleeding disorder (hemophilia 
B) (20). Although a high degree of factor IX inhibition has 
been associated with hemorrhagic transformation in a murine 
stroke model, it does interfere with thrombus formation (21), 
supporting a decisive role for the intrinsic pathway in vessel 
occluding fi  brin formation.
To confi  rm that FXII contributes to ischemic brain injury 
via activation of the intrinsic coagulation pathway, we mea-
sured fi  brin formation in the infarcted hemisphere by quanti-
tative immunoblot analysis of urea-insoluble tissue extracts. 
We used the antibody 59D8, which recognizes a neo-epitope 
exposed on fi  brin following thrombin-dependent cleavage of 
fi  brinogen, and which lacks cross-reactivity with the precur-
sor protein (22). There was considerably reduced fi  brin accu-
mulation in the ischemic hemisphere of FXII−/− and FXI−/− 
mice compared with WT mice (Fig. 2 B). Immunohisto-
chemistry consistently demonstrated intravascular fi  brin de-
posits occluding vessels in WT mice and dramatically reduced 
fi  brin deposits in FXII−/− and FXI−/− mice. Platelets were 
identifi  ed by glycoprotein (GP) Ib colocalization with fi  brin 
clots in >80% of thrombi, suggesting that FXII-mediated 
fi  brin formation and platelets synergize to form occluding 
thrombi in vessels distal to MCA occlusions (Fig. 2 C). Ac-
cordingly, histological sections of infarcted brain tissue from 
WT mice showed ischemic neurodegeneration associated 
with numerous occlusions of vessel lumina. In comparison, 
tissue injury in corresponding areas of FXII−/− and FXI−/− 
mice was markedly less severe than for WT mice, with a clear 
reduction in the number of occluded vessels (Fig. 2 D).
Cumulatively, our data suggest that protection from ce-
rebral ischemia conferred by FXII defi  ciency is due to im-
paired microvascular thrombus formation caused by defective 
Figure 2.  Comparison of FXII−/− and FXI−/− mice in the tMCAO 
model. (A) Representative TTC-stained coronal sections of FXI−/− and WT 
mice. Infarct volumes were assessed 24 h after tMCAO (WT, n = 18 and 
FXI−/−, n = 11; *P < 0.05). (B) Accumulation of fi  brin in the infarcted (+) 
and contralateral (−) hemispheres of WT, FXI−/−, and FXII−/− mice. Fibrin 
formation 24 h after ischemia was analyzed by immunoblotting using the 
fi  brin-specifi  c antibody 59D8. (C) Immunohistochemical colocalization of 
fi  brin (59D8 antibody) and platelets (anti-GP Ib antibody) in the lumens of 
microvessels after 24 h in the infarcted hemisphere of WT mice. Bar, 
100 μm. (D) Hematoxylin and eosin–stained sections of corresponding 
territories in the ischemic hemispheres of WT, FXI−/−, and FXII−/− mice. 
The dark arrows indicate blood vessels that are shown magnifi  ed in the 
inserts. Note the reduced microvascular patency in the ischemic areas of 
WT animals compared with FXI−/− and FXII−/− mice. Bar, 25 μm. The 
  asterisk denotes the ischemic lesion.516  FXII AND STROKE | Kleinschnitz et al.
fi   brin formation through the intrinsic pathway. Further 
  analyses will be necessary to clarify the precise molecular 
mechanism for FXII activation in ischemic vessels and the 
additional contribution of other FXII-associated pathways, 
such as the complement and kallikrein-kinin systems, that 
have been shown to contribute to the pathology of cerebral 
ischemia (23, 24).
As congenital FXII defi  ciency protects mice from isch-
emic stroke, pharmacological targeting of FXII should 
provide similar protection. H-D-Pro-Phe-Arg-chlorometh-
ylketone (PCK) irreversibly inhibits the amidolytic activity 
of activated FXII (FXIIa) and plasma kallikrein-mediated 
activation of FXII (25, 26). In accordance with its eff  ects 
on human plasma in vitro (Fig. 3 A, open triangles), PCK 
increased the aPTT in a dose-dependent manner when added 
to plasma from WT mice (Fig. 3 A, fi  lled triangles) but did 
not prolong the prothrombin time (PT; a test for factor VIIa/
TF–initiated activation of the extrinsic pathway of coagula-
tion, fi  lled and open squares). [ID]FIG3[/ID] To test the protective poten-
tial of FXIIa inhibition, WT mice received PCK (8 μg/g 
body weight) before tMACO. PCK treatment prolonged the 
aPTT (61 ± 15 s) and reduced infarcted brain volume at 24 h 
compared with WT mice (23 ± 25 mm3 and 56 ± 36 mm3, 
respectively, P < 0.05; Fig. 3 B). PCK-treated mice showed 
a signifi  cantly better Bederson score (2.4 ± 0.4 for treated 
animals and 3.6 ± 0.8 for untreated animals, P < 0.0001; 
Fig. 3 C) and motor function (grip test score 3.7 ± 0.5 for 
PCK-treated animals vs. 1.9 ± 1.4 for untreated animals, 
P < 0.01). Western blot and immunohistochemical analyses of 
brain tissue using antibody 59D8 confi  rmed that PCK treat-
ment had a striking eff  ect on fi  brin deposition, vessel occlu-
sion, and ipsilateral brain damage after tMCAO compared 
with untreated control mice (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20052458/DC1).
Dose–response analysis indicated that >4 μg/ml PCK 
was necessary to signifi  cantly inhibit fi  brin formation, consis-
tent with previous work showing that mice heterozygous for 
a FXII-null allele and WT mice exhibit similar arterial throm-
bus formation (12). Corroborating the concept that FXIIa 
inhibition is thrombo-protective, other FXII-blocking 
agents, such as anti-FXII antibodies and maize trypsin inhibi-
tor, had similar eff  ects to PCK on thrombus formation in-
duced by arterial injury (unpublished data).
Although PCK infusion prolonged the aPTT of mice, 
normal hemostasis was not aff  ected in a tail amputation assay 
(bleeding time 291 ± 134 s for treated animals and 278 ± 99 s 
for untreated animals). In comparison, the commonly used 
clinical anticoagulant heparin (0.2 U/g) prolonged the aPTT 
to an equivalent degree, but markedly prolonged the tail 
bleeding time to >20 min (n = 14; Fig. 4 A), indicating a 
substantial risk for hemorrhage.[ID]FIG4[/ID] To further analyze the im-
pact of FXIIa inhibition on the dynamics of infarct develop-
ment and the risk of secondary hemorrhagic transformation, 
we used serial magnetic resonance imaging (MRI) on living 
mice. In FXII−/− mice and WT mice treated with PCK, ar-
eas of hyperintensity on T2-weighted images typical of acute 
cerebral infarction were <10% of the corresponding area in 
untreated WT mice 24 h after tMCAO (P < 0.0001; Fig. 4 B), 
confirming assessments with TTC staining. Importantly, 
follow-up MRI at days 3 and 7 post-tMCAO demonstrated 
that ischemic lesions in FXII−/− and PCK-treated WT mice 
always presented as hyperintense lesions on T2-weighted 
gradient echo images, an MRI protocol for detection of 
bleeding. Hypointense areas, which typically indicate hemor-
rhage, were absent in all animals, supporting the notion that 
FXII defi  ciency does not increase the risk of infarct or reper-
fusion-associated bleeding compared with WT control mice, 
even at more advanced stages of infarct development.
In summary, inhibition of FXII activity impairs patho-
logical fi  brin formation and salvages brain tissue during cere-
bral ischemia in mice. Importantly, neuroprotection through 
targeted inhibition of FXII did not increase bleeding during 
the acute infarct stage or in the recovery period. Therefore, 
the data of the current study and previous analyses using other 
Figure 3.  Inhibition of FXII activity inhibits clotting in vitro and 
thrombus formation in vivo. (A) Normal human plasma (open symbols) 
and WT mouse plasma (fi  lled symbols) were incubated with increasing 
concentrations of PCK (1–200 μg/ml fi  nal concentration), an inhibitor 
that blocks FXIIa activity and activation. Clotting was initiated by adding 
kaolin and CaCl2 (triangles) or TF (squares) to determine the aPTT and the 
PT, respectively. (B and C) PCK (8 μg/g of body weight) was infused intra-
venously into WT mice (n = 8) before tMCAO. 24 h after stroke, treated 
animals were analyzed and compared with untreated controls (ctrl, n = 18 
per group). (B) Infarct volumes determined from TTC-stained sequential 
coronal sections (*P < 0.05) and (C) the neurological function assessed by 
the Bederson Score for PCK-treated and untreated mice (***P < 0.0001).JEM VOL. 203, March 20, 2006  517
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models of arterial thrombosis (12) strongly support the evalu-
ation of FXII as a novel pharmacological target for safe 
  anticoagulation in humans. FXII inhibition may be useful 
when used prophylactically on a chronic basis, or for short-
term therapy during procedures or conditions associated with 
increased risk of thrombosis, including vascular procedures 
and during surgery, without compromising hemostasis at a 
wound site. Finally, these fi  ndings challenge current concepts 
of coagulation by demonstrating that fi  brin-generating mech-
anisms in pathologic vessel occlusion involve pathways dis-
tinct from those operating during normal hemostasis.
MATERIALS AND METHODS
Animals. All procedures and animal studies were approved by the Bezirk-
sregierung of Unterfranken. FXII−/− and FXI−/− mice used in this study 
were described previously (12). 8–20-wk-old male and female mice back-
crossed for not less than nine generations to C57BL/6J background were 
used for experiments, and WT littermate animals were used as controls. 
The peptide-based FXII inhibitor PCK was obtained from Bachem and 
  administered intravenously.
Coagulation analysis. PT and aPTT clotting times were determined as 
described (12).
Detection of intracerebral fi  brin. Tissue fi  brin deposits were isolated as 
described, and the amount of fi  brin β-chains normalized to identical cerebral 
tissue weight was determined by Western blot using the fi  brin-specifi  c mAb 
59D8 (22).
Histopathological and immunofl  uorescence studies. Formalin-fi  xed 
brains embedded in paraffi   n (Histolab Products AB) were cut into 4-μm-
thick sections and mounted. After removal of paraffi   n, tissues were stained 
with hematoxylin and eosin (Sigma-Aldrich). For immunohistochemistry, 
fi  brin was detected using mAb 59D8, and platelets were detected using a 
mAb against GP Ib β (CD42c; Emfret). Images were generated using a 
Nikon E600 microscope (60× magnifi  cation) equipped with a Nikon C1 
confocal laser scanning system.
Tail bleeding time. The bleeding time of mice was assessed as published 
earlier (12).
Murine stroke model. tMCAO was induced under inhalation anesthesia 
using the intraluminal fi  lament (6021PK10; Doccol Company) technique 
(27). After 60 min, the fi  lament was withdrawn to allow reperfusion. Laser 
Doppler fl  owmetry (Moor Instruments Ltd.) was used to monitor cerebral 
blood fl  ow. For measurements of ischemic brain volume, animals were killed 
24 h after induction of MCAO and infarctions were stained in 2% TTC. 
Brain infarct volumes were calculated and corrected for edema as described 
(28). To determine the eff  ect of inhibition of FXII activity in WT mice, 
PCK (8 μg/g body weight) was administered intravenously immediately be-
fore tMCAO. In some experiments, human FXII (huFXII; American Diag-
nostics) was injected intravenously immediately before the experiment.
Neurological testing. Neurological function was assessed by two indepen-
dent and blinded investigators 24 h after tMACO. Global neurological status 
was scored according to Bederson et al. (29). Motor function was graded 
  using the grip test (30).
Stroke assessment by MRI. MRI was performed 24 h, and again 3 and 
7 d after stroke on a 1.5 T unit (Vision; Siemens) under inhalation anesthesia. 
A custom made dual channel surface coil was used for all measurements 
(A063HACG; Rapid Biomedical). The MR protocol included a coronal 
T2-w sequence (slice thickness 2 mm), and a coronal T2-w gradient echo 
CISS sequence (Constructed Interference in Steady State; slice thickness 
1 mm). Mr images were transferred to an external workstation (Leonardo; 
Siemens) for data processing, and were read blinded to group assignment. 
Infarct volumes were calculated by planimetry of the hyperintense area on 
high-resolution CISS images.
Statistics. Statistical analyses were made using the two-tailed student’s t test. 
p values <0.05 were considered statistically signifi  cant. All results are given 
as mean ± 1 SD.
Online supplemental material. Fig. S1 shows that no obvious diff  er-
ences in the cardio- and cerebrovascular phenotype were observed be-
tween FXII−/− and WT mice. Fig. S2 gives evidence that treatment 
with the FXII inhibitor PCK reduces fi   brin formation, intravascular 
fi  brin deposition, and ischemic brain damage in the ischemic hemispheres 
Figure 4.  Inhibition of FXII activity does not affect normal hemo-
stasis. (A) Tail bleeding times for PCK-treated (8 μg/g of body weight) 
and untreated control mice (ctrl; n = 12 per group; ***P < 0.0001). 
  Heparin-infused (hep) mice are shown for comparison. (B) Serial coronal 
T2-weighted MRI brain images from untreated (ctrl), PCK-treated (8 μg/g 
of body weight), and FXII−/− mice at days 1, 3, and 7 after tMCAO (n = 5 
per group). The asterisk indicates hydrocephalus of the left lateral ven-
tricle as an indicator of infarct-related swelling.518  FXII AND STROKE | Kleinschnitz et al.
compared with control mice. Supplemental Materials and methods are also 
included. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20052458/DC1).
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